DESIREE CHIZMADIA: Open Payments
NPI 1801309695 · CLEVELAND, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$6,742 in 45 payments from 8 companies in 2025. Trend: 2023 $2,370 · 2024 $1,740 · 2025 $6,742
Consulting: $4,351Food & beverage: $1,400Travel & lodging: $992
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 19 | $3,932 |
| GENZYME CORPORATION | 6 | $1,578 |
| TG Therapeutics, Inc. | 5 | $696 |
| Genentech, Inc. | 5 | $302 |
| Biogen, Inc. | 5 | $120 |
| Genentech USA, Inc. | 2 | $48 |
| Vanda Pharmaceuticals Inc. | 2 | $39 |
| Celgene Corporation | 1 | $27 |
Products named: KESIMPTA, BRIUMVI, Ocrevus, Ocrevus Zunovo, TYSABRI, PONVORY, ZEPOSIA, VUMERITY.
Industry payments across OH — which companies pay providers there.
